@article{4d757670b32b4e0a8f66bd0111994eff,
title = "Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody",
abstract = "RIT (Radioimmunotherapy) has become an attractive strategy in cancer treatment, but still faces important drawbacks due to poor tumor penetration and undesirable pharmacokinetics of the targeting vehicles. Smaller radiolabeled antibody fragments and peptides feature highly specific target accumulation, resulting in low accumulation in healthy tissue, except for the kidneys. Nanobodies are the smallest (MW",
keywords = "HER2, nanobody, targeted radionuclide therapy, 177-Lutetium",
author = "Matthias D'huyvetter and C{\'e}cile Vincke and Catarina Xavier and An Aerts and Nathalie Impens and Sarah Baatout and {De Raeve}, Hendrik and Serge Muyldermans and Vicky Caveliers and Nick Devoogdt and Tony Lahoutte",
note = "Score = 10",
year = "2014",
month = apr,
doi = "10.7150/thno.8156",
language = "English",
volume = "4",
pages = "708--720",
journal = "Theranostics",
issn = "1838-7640",
publisher = "Ivyspring International Publisher",
number = "7",
}